
- Pharmaceutical Commerce - May/June 2015
TrialCard takes closer aim at market access solutions
Leading copay-coupon provider expands its patient services with private equity help
TrialCard, Inc. (Cary, NC) has ridden the wave of growth in copay cards for patients for over a decade; now, with the boost from its partnership with the Denver, CO-based private equity firm, Excellere Partners, the company is looking to broaden its base of services to pharma marketers. Jointly, the two companies have just announced winning a “Deal of the Year” award from a local organization, the Association for Corporate Growth, Raleigh-Durham.
The partnership “will allow TrialCard to leverage valuable relationships in the healthcare space to drive organic growth as well as explore strategic acquisition opportunities that will further solidify its position as an industry leader,” according to a company statement. TrialCard has been experiencing “high growth,” according to a company representative, with its
“TrialCard is in a unique position to build upon its history of leadership within the patient access and medication adherence market. We are focused on enhancing the value proposition that the company provides for customers through a combination of service optimization, organic growth initiatives, and complementary acquisitions that further improve patient outcomes and drive attractive return on investments to current and prospective customers,” added Brad Cornell, principal at Excellere.
Articles in this issue
about 11 years ago
Understanding the companion-diagnostics environmentabout 11 years ago
HPCLC Spring Meeting recapabout 11 years ago
Pharmaceutical Commerce at 10about 11 years ago
A Conversation with Shabbir Dahod, TraceLinkabout 11 years ago
A Big Data approach to patient engagement and adherenceabout 11 years ago
What makes specialty pharmacies 'special'?about 11 years ago
2015 Product Security Reportabout 11 years ago
Compliance packaging vendors keep innovatingover 11 years ago
US spending on drugs hit $373.9 billion in 2014, up 13.1%



